The Utility of Osteopathic Manipulative Medicine in Weaning Patients from the Ventilator Pilot Trial
Launched by OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES · Mar 18, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of Osteopathic Manipulative Medicine (OMM) to help patients who are on ventilators breathe on their own again. The goal is to see if OMM can speed up the process of getting off the ventilator for patients who are not improving after being on it for more than 48 hours. Researchers will also look at whether OMM affects patients’ overall health, including how stable their blood pressure is and whether they require reintubation (going back on the ventilator) after being taken off. This is a pilot study, which means it is a smaller initial study to gather information before a larger study is planned.
To join this study, patients need to be between 65 and 85 years old, have acute respiratory failure (which means they are having trouble breathing), and not be making progress in weaning off the ventilator. They must be under the care of a lung specialist during their treatment. However, some patients will not be eligible, such as those with certain severe neurological conditions or serious heart issues. If someone participates, they will receive OMM treatment, and the research team will closely monitor their progress to see how it affects their ability to breathe without the ventilator.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Acute respiratory failure (hypoxic, hypercapnic, or neuromuscular)
- • 2. Not making satisfactory progress with weaning after being on the ventilator for more than 48 hours
- • 3. Clinical stability for pressure support trial with ventilator to monitor ventilation progression
- • 4. Pulmonology must be following the patient for standardized ventilator management approach and interventions as needed
- • 5. Medical power of attorney (POA) or legally authorized representative (LAR) who is able to consent subject for trial enrollment and treatment
- • 6. Patients who were not referred to the OMM service
- Exclusion Criteria:
- • 1. Age less than 18 years old or more than 85 years old
- • 2. BMI\>60
- • 3. Moderate/severe neurological disease with expectation of non-progression off the ventilator or poor quality of life predicted (including end-stage dementia with the expectation of non-progression off ventilator, multiple sclerosis, ALS, anoxic brain injury, etc)
- • 4. Status epilepticus or EEG result pending
- • 5. Post-arrest hypothermia protocol
- • 6. Acute stroke
- • 7. Acute rib fractures preventing the implementation of the treatment protocol
- • 8. Acute spinal injury preventing the implementation of the treatment protocol
- • 9. Recent head injury requiring close clinical monitoring
- • 10. Ejection Fraction less than 15%
- • 11. Pleural effusion requiring procedural intervention or inhibiting ventilator progress
- • 12. Pericardial effusion or tamponade requiring procedural intervention or inhibiting ventilator progress
- • 13. ACLS/cardiac arrest within the past 72 hours
- • 14. Confirmed opioid overdose with positive urine drug screen and response to naloxone
- • 15. Patients who were referred to the OMM service
About Oklahoma State University Center For Health Sciences
Oklahoma State University Center for Health Sciences (OSU-CHS) is a leading academic institution dedicated to advancing health education, research, and clinical practice. With a strong emphasis on interdisciplinary collaboration, OSU-CHS conducts innovative clinical trials aimed at improving patient outcomes and addressing pressing healthcare challenges. The center is committed to fostering a diverse and inclusive research environment, leveraging cutting-edge technology and expert faculty to enhance the quality of life in communities both locally and globally. Through its rigorous clinical research initiatives, OSU-CHS plays a vital role in translating scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Amber Hood, DFS
Study Director
OSU CHS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported